Veena John
Hematology & Oncology · Lake Success, NYNPI 1356475610
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,405 of the $22,408 with a category attached, or 95.5%. AstraZeneca accounts for 82.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $8,314 and has fallen 66.9% since, to $2,749 in 2025.
Across 23 payments — averaging $974.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- Eisai Inc.$2K
- GSK$1K
- AbbVie$135
- Genmab U.S., Inc.$69
- Eli Lilly$57
- plus $61 from 3 others
Across 432 payments — averaging $5365.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$562K
- AstraZeneca$435K
- GSK$427K
- Tesaro, Inc.$395K
- Deciphera Pharmaceuticals Inc.$236K
- Genentech, Inc.$112K
- plus $151K from 3 others
What the payments were for
- Consulting fees$21,40596%
- Travel & lodging$1801%
- Food & beverage$7713%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $18,417 |
| Eisai Inc. | 1 | $2,370 |
| GSK | 1 | $1,300 |
| AbbVie | 1 | $135 |
| Genmab U.S., Inc. | 1 | $69 |
| Eli Lilly | 1 | $57 |
| Lilly USA, LLC | 1 | $27 |
| Merck | 2 | $22 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,408 in reported general payments places this provider in the 80th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 30 | $710,410 |
| LynparzaOlaparib | 29 | $481,124 |
| EliquisApixaban | 52 | $35,171 |
| Prochlorperazine Maleate | 142 | $1,316 |
| Dexamethasone Sodium Phosphate | 32 | $1,119 |
| Dexamethasone | 110 | $972 |
| Letrozole | 45 | $848 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 25 | $313 |
| Gabapentin | 52 | $197 |
| Potassium Chloride | 24 | $148 |
| Pantoprazole Sodium | 15 | $124 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $119 |
| Ondansetron Hcl | 13 | $79 |
| Ciprofloxacin Hcl | 18 | $74 |
| Metoclopramide Hcl | 18 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $2,370 | $710,41030 claims |
| AstraZenecaLynparza | $18,417 | $481,12429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Lake Success
- Francis ArenaLake Success$1M
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.